Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)

Nom du journal : Angiogenesis

Année : 2019

Volume : doi: 10.1007/s10456-019-09697-7 [Epub ahead of print]

Auteurs: Tredan O, Chevrier M, Cabel L, Levy C, Lorgis V, Lemonnier J, Bidard FC, Jacot W, Dubot C, Mouret-Reynier MA, Jouannaud C, Dalenc F, Savignoni A, Ferrero JM, Goncalves A, Pierga JY, Tanguy ML, Luporsi E, Debled M, Vasseur A,